AR and prostate carcinoma: Additionally, while targeted forms of therapy exist that can be used for metastatic CRPC, we must continue to identify cancer-associated markers for the treatment of prostate cancers that have a resistance to hormone therapy and no androgen receptor (ARneg-AI prostate cancer).